Treatments & Services

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

Breast

Gastrointestinal

  • Nivolumab +/- Ipilimumab with Fluorouracil plus Cisplatin in Esophageal Squamous Cell

    A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma


  • Nivolumab for Esophageal Squamous Cell Carcinoma

    A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation


Hematology

Liver

Lung

Lymphoma

  • Polatuzumab Vedotin with R-CHP versus R-CHOP in DLBCL

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial comparing the efficacy and safety of Polatuzumab Vedotin in combination with Rituximab and CHP (R-CHP) and CHOP (R-CHOP) in previously untreated patients with Diffuse Large B-Cell Lymphoma


  • ABP798 versus Rituximab in Non-Hodgkin Lymphoma

    A Randomized, Double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 postiive B-Cell Non-Hodgkin Lymphoma (NHL)


  • Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

    A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above


  • Rituximab +/- Ibrutinib for Follicular Lymphoma

    A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma


  • TGR-1202 in patients with DLBCL, FL, SLL, or MZL

    A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma


  • Lenalidomide/Rituxan for FL, MZ, ML

    A phase 3b randomized study of Lenalidomide (CC-5013) plus Rituximab maintenance therapy followed by Lenalidomide single-agent maintenance versus Rituximab maintenance in subjects with relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma


Pancreatic

Prostate

Renal

Solid Tumors